Results 181 to 190 of about 453,251 (315)

Motorized DNAzymes Drive Enhanced Electrochemical Biosensing for Rapid Bacterial Detection

open access: yesSmall Methods, EarlyView.
The micromotor DNAzyme analyzer (Motolyzer) enables sensitive electrochemical detection of Legionella pneumophila proteins in unprocessed samples with high specificity. Upon target recognition, DNAzymes actively release redox barcodes, which are detected on DNA‐functionalized electrodes.
Amir Ali Akhlaghi   +9 more
wiley   +1 more source

Sphinganine‐phosphate prevents influenza infection via promoting CD8+ T cells proliferation and activation

open access: yesVIEW, EarlyView.
This study established clinical cohorts of respiratory viral infections and identified sphinganine‐phosphate (SA) as a metabolite significantly upregulated post‐infection through metabolomic analysis. In vitro and in vivo experiments demonstrated that SA promotes the generation of effector CD8+ T cells via the SOCS1/JAK1/STAT1 pathway, which ...
Zhongwen Hu   +10 more
wiley   +1 more source

Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO‐2b/3 and ALLEGRO‐LT Clinical Studies for Alopecia Areata

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Ritlecitinib is an oral JAK3/TEC family kinase inhibitor approved for individuals aged ≥ 12 years with severe alopecia areata. Here we report interim efficacy and safety results with ritlecitinib up to Month 24 in the Asian subpopulation from the ALLEGRO phase 2b/3 and ALLEGRO‐LT studies.
Rie Ueki   +13 more
wiley   +1 more source

Cost‐Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT The efficacy and safety of ritlecitinib, a dual inhibitor of Janus kinase 3 (JAK3) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases, have been demonstrated in the ALLEGRO phase 2b/3 trial that enrolled patients aged ≥ 12 years with alopecia areata (AA) and ≥ 50% scalp hair loss.
Akira Yuasa   +8 more
wiley   +1 more source

Structure, function and inhibition of poly(ADP-ribose)polymerase, member 14 (PARP14) [PDF]

open access: yes, 2018
Levonis, Stephan M   +3 more
core   +1 more source

Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review

open access: yesAustralasian Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy